隋兴华
副教授，硕士生导师
电子邮箱
suixingh@mail.sysu.edu.cn
个人经历
教育经历
2006－2012中国科学院植物研究所，博士，生态学
2002－2006山东大学数学与系统科学学院，本科，应用数学
工作经历
2012－2018中山大学生命科学学院，博士后
2019－2024中山大学药学院（深圳），特聘副研究员
2024 至今中山大学药学院（深圳），副教授
研究方向
课题组在肿瘤免疫治疗领域开展生物信息学与药物化学交叉领域研究，包括单细胞组学、深度学习、药物信息学、药物筛选及免疫治疗新靶点发现。主持中国博士后基金、国家自然科学基金、广东省自然科学基金面上项目及深圳市科创委面上项目，在J Exp Clin Cancer Res、Sci China Life Sci、J Control Release、Acta Pharm Sin B、J Immunother Cancer等杂志发表SCI论文32篇，其中第一作者或共通讯作者9篇。
科研项目
国家自然科学基金委员会，青年科学基金项目，2020-01-01至2022-12-31，21万元，主持
广东省基础与应用研究基金委员会，面上项目，2024-01至2026-12，15万元，主持
广东省基础与应用基础研究基金委员会，区域联合基金-重点项目，2022-10至2025-09，100万元，参与
深圳市科技创新委员会，基础研究(面上项目)，2020-05至2023-05，30万元，主持
代表论著
(1)Zhou Xiuman, Qian Yuzhen, Ling Chen, He·Zhuoying, Shi Peishang, Gao Yanfeng* , Sui Xinghua*; An-Integrated.Framework,for-Prognosis-Prediction-and-DrugResponse Modeling in Colorectal Liver Metastasis Drug Discovery. Journal of Translational Medicine, 2024, Mar 30,22:321
(2)Yang Xin, Li Wangiong, Li Shuzhen, Chen Shaomeng, Hu Zheng, He Zhuoying, Zhu Xueqin, Niu Xiaoshuang, Zhou Xiuman, Li Huihao, XiaoYoumei, Liu Juan, Sui Xinghua, Chen Guanyu, Gao Yanfeng. Fish oil-based microemulsion can efficiently deliver oral peptide blocking PDI/PD-L1 and simultaneously induce ferroptosis for cancer immunotherapy. Journal of Controlled Release. 2024 Jan; 365 : 654-667.
(3)Sui Xinghua, Niu Xiaoshuang, Zhou Xiuman, Gao Yanfeng. Peptide drugs: a new direction in cancer immunotherapy. Cancer Biology & Medicine 2023 ·Dec·7:j.issn.2095-3941.2023.0297.
(4)Shen Wenhui, Shi Peishang, Dong Qingyu,·Zhou Xiuman, Chen Chunxia, Sui·Xinghua, Tian Wentong, Zhu Xueqin, Wang Xiaoxi, Jin Shengzhe, Wu Yahong, Chen Guanyu, Qiu·Lu, Zhai Wenjie*, GaoYanfeng*. Discovery of a novel-dual-targeting D-peptide to-blockCD24/Siglec-10 and-PD-1/PD-LI interaction-and synergize with radiotherapy for cancer immunotherapy. Journal of Immunotherapy of Cancer. 2023 Jun;11(6):e007068.
(5)Sui, Xinghua; Chen, Chunxia; Zhou, Xiuman; Wen, Xueyan; Shi, Chao; Chen, Guanyu; Liu, Juan; He, Zhuoying; Yao, Yongjie; Li, Yin; Gao, Yanfeng ; Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma, Journal of Experimental & Clinical Cancer Research, 2023, 42(1): 51
(6)Hu, Zheng; Li, Wanqiong; Chen, Shaomeng; Chen, Danhong; Xu, Ran; Zheng, Danlu; Yang, Xin; Li, Shuzhen; Zhou, Xiuman; Niu, Xiaoshuang; Xiao, Youmei; He, Zhuoying; Li, Huihao; Liu, Juan; Sui, Xinghua ; Gao, Yanfeng ; Design of a Novel Chimeric Peptide via Dual Blockade of CD47/SIRPα and PD-1/PD-L1 for Cancer Immunotherapy, Science China Life Sciences, 2023, 66(10): 2310-2328
(7)Ling,Chen; Zhou, Xiuman; Gao, Yanfeng; Sui, Xinghua ; Identification of lmmune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response, Pharmaceuticals,2022，15(5):605
(8)Chen, Chunxia; Sui, Xinghua; Ning, Haoming;Sun, Yixuan; Du, Jiangfeng; Chen, Xiaotong;Zhou, Xiuman; Chen, Guanyu; Shen, Wenhui; Pang, Liwei; Zhou, Xiaowen; Shi, Ranran; Li, Wangiong; Wang,Hongfei: Zhao, Wenshan; Zhai, Wenjie; Qi, Yuanming; Wu, Yahong; Gao, Yanfeng ;Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression, Journal for ImmunoTherapy of Cancer, 2022, 10(11):e005503
